Issue
The effects of caveolin1 on β cell proliferation
Corresponding Author(s) : Longyi Zeng
Cellular and Molecular Biology,
Vol. 64 No. 1: Issue 1
Abstract
Keywords
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX
- References
- Ogurtsova K, da Rocha Fernandes JD, Huang Y et al. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. Jun 2017; 128: 40-50.
- Boutayeb A, Boutayeb S. The burden of non communicable diseases in developing countries. Int J Equity Health. Jan 14 2005; 4(1): 2.
- DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. Jul 04 2000; 133(1): 73-74.
- Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. Jan 2003; 52(1): 102-110.
- Rhodes CJ. Type 2 diabetes-a matter of beta-cell life and death? Science. Jan 21 2005; 307(5708): 380-384.
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. Sep 12 1998; 352(9131): 854-865.
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. Sep 12 1998; 352(9131): 837-853.
- Glenney JR, Jr., Zokas L. Novel tyrosine kinase substrates from Rous sarcoma virus-transformed cells are present in the membrane skeleton. J Cell Biol. Jun 1989; 108(6): 2401-2408.
- Glenney JR, Jr. Tyrosine phosphorylation of a 22-kDa protein is correlated with transformation by Rous sarcoma virus. J Biol Chem. Dec 05 1989; 264(34): 20163-20166.
- Nystrom FH, Chen H, Cong LN, Li Y, Quon MJ. Caveolin-1 interacts with the insulin receptor and can differentially modulate insulin signaling in transfected Cos-7 cells and rat adipose cells. Mol Endocrinol. Dec 1999; 13(12): 2013-2024.
- Cohen AW, Razani B, Wang XB et al. Caveolin-1-deficient mice show insulin resistance and defective insulin receptor protein expression in adipose tissue. Am J Physiol Cell Physiol. Jul 2003; 285(1): C222-235.
- Yamamoto M, Toya Y, Schwencke C, Lisanti MP, Myers MG, Jr., Ishikawa Y. Caveolin is an activator of insulin receptor signaling. J Biol Chem. Oct 09 1998; 273(41): 26962-26968.
- Cohen AW, Combs TP, Scherer PE, Lisanti MP. Role of caveolin and caveolae in insulin signaling and diabetes. Am J Physiol Endocrinol Metab. Dec 2003; 285(6): E1151-1160.
- Razani B, Engelman JA, Wang XB et al. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem. Oct 12 2001; 276(41): 38121-38138.
- Galbiati F, Volonte D, Engelman JA et al. Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. EMBO J. Nov 16 1998; 17(22): 6633-6648.
- Drab M, Verkade P, Elger M et al. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science. Sep 28 2001; 293(5539): 2449-2452.
- Fodor SPA. Massively Parallel Genomics. Science. 1997; 277(5324): 393-403.
- Dudda-Subramanya R, Lucchese G, Kanduc D, Sinha AA. Clinical applications of DNA microarray analysis. J Exp Ther Oncol. Nov-Dec 2003; 3(6): 297-304.
- Hamaguchi K, Gaskins HR, Leiter EH. NIT-1, a pancreatic beta-cell line established from a transgenic NOD/Lt mouse. Diabetes. Jul 1991; 40(7): 842-849.
- Poy MN, Eliasson L, Krutzfeldt J et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature. Nov 11 2004; 432(7014): 226-230.
- Halperin F, Lopez X, Manning R, Kahn CR, Kulkarni RN, Goldfine AB. Insulin augmentation of glucose-stimulated insulin secretion is impaired in insulin-resistant humans. Diabetes. Feb 2012; 61(2): 301-309.
- Parton RG, Simons K. The multiple faces of caveolae. Nat Rev Mol Cell Biol. Mar 2007; 8(3): 185-194.
- Engelman JA, Zhang XL, Galbiati F, Lisanti MP. Chromosomal localization, genomic organization, and developmental expression of the murine caveolin gene family (Cav-1, -2, and -3). Cav-1 and Cav-2 genes map to a known tumor suppressor locus (6-A2/7q31). FEBS Lett. Jun 16 1998; 429(3): 330-336.
- Shajahan AN, Wang A, Decker M, Minshall RD, Liu MC, Clarke R. Caveolin-1 tyrosine phosphorylation enhances paclitaxel-mediated cytotoxicity. J Biol Chem. Feb 23 2007; 282(8): 5934-5943.
- Jasmin JF, Frank PG, Lisanti MP. Caveolins and Caveolae. Advances in Experimental Medicine & Biology. 2005.
- Fagerholm S, Ortegren U, Karlsson M, Ruishalme I, Stralfors P. Rapid insulin-dependent endocytosis of the insulin receptor by caveolae in primary adipocytes. PLoS One. Jun 19 2009; 4(6): e5985.
- Yang Y, Tong Y, Gong M et al. Activation of PPARbeta/delta protects pancreatic beta cells from palmitate-induced apoptosis by upregulating the expression of GLP-1 receptor. Cell Signal. Feb 2014; 26(2): 268-278.
References
References
Ogurtsova K, da Rocha Fernandes JD, Huang Y et al. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. Jun 2017; 128: 40-50.
Boutayeb A, Boutayeb S. The burden of non communicable diseases in developing countries. Int J Equity Health. Jan 14 2005; 4(1): 2.
DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. Jul 04 2000; 133(1): 73-74.
Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. Jan 2003; 52(1): 102-110.
Rhodes CJ. Type 2 diabetes-a matter of beta-cell life and death? Science. Jan 21 2005; 307(5708): 380-384.
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. Sep 12 1998; 352(9131): 854-865.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. Sep 12 1998; 352(9131): 837-853.
Glenney JR, Jr., Zokas L. Novel tyrosine kinase substrates from Rous sarcoma virus-transformed cells are present in the membrane skeleton. J Cell Biol. Jun 1989; 108(6): 2401-2408.
Glenney JR, Jr. Tyrosine phosphorylation of a 22-kDa protein is correlated with transformation by Rous sarcoma virus. J Biol Chem. Dec 05 1989; 264(34): 20163-20166.
Nystrom FH, Chen H, Cong LN, Li Y, Quon MJ. Caveolin-1 interacts with the insulin receptor and can differentially modulate insulin signaling in transfected Cos-7 cells and rat adipose cells. Mol Endocrinol. Dec 1999; 13(12): 2013-2024.
Cohen AW, Razani B, Wang XB et al. Caveolin-1-deficient mice show insulin resistance and defective insulin receptor protein expression in adipose tissue. Am J Physiol Cell Physiol. Jul 2003; 285(1): C222-235.
Yamamoto M, Toya Y, Schwencke C, Lisanti MP, Myers MG, Jr., Ishikawa Y. Caveolin is an activator of insulin receptor signaling. J Biol Chem. Oct 09 1998; 273(41): 26962-26968.
Cohen AW, Combs TP, Scherer PE, Lisanti MP. Role of caveolin and caveolae in insulin signaling and diabetes. Am J Physiol Endocrinol Metab. Dec 2003; 285(6): E1151-1160.
Razani B, Engelman JA, Wang XB et al. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem. Oct 12 2001; 276(41): 38121-38138.
Galbiati F, Volonte D, Engelman JA et al. Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. EMBO J. Nov 16 1998; 17(22): 6633-6648.
Drab M, Verkade P, Elger M et al. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science. Sep 28 2001; 293(5539): 2449-2452.
Fodor SPA. Massively Parallel Genomics. Science. 1997; 277(5324): 393-403.
Dudda-Subramanya R, Lucchese G, Kanduc D, Sinha AA. Clinical applications of DNA microarray analysis. J Exp Ther Oncol. Nov-Dec 2003; 3(6): 297-304.
Hamaguchi K, Gaskins HR, Leiter EH. NIT-1, a pancreatic beta-cell line established from a transgenic NOD/Lt mouse. Diabetes. Jul 1991; 40(7): 842-849.
Poy MN, Eliasson L, Krutzfeldt J et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature. Nov 11 2004; 432(7014): 226-230.
Halperin F, Lopez X, Manning R, Kahn CR, Kulkarni RN, Goldfine AB. Insulin augmentation of glucose-stimulated insulin secretion is impaired in insulin-resistant humans. Diabetes. Feb 2012; 61(2): 301-309.
Parton RG, Simons K. The multiple faces of caveolae. Nat Rev Mol Cell Biol. Mar 2007; 8(3): 185-194.
Engelman JA, Zhang XL, Galbiati F, Lisanti MP. Chromosomal localization, genomic organization, and developmental expression of the murine caveolin gene family (Cav-1, -2, and -3). Cav-1 and Cav-2 genes map to a known tumor suppressor locus (6-A2/7q31). FEBS Lett. Jun 16 1998; 429(3): 330-336.
Shajahan AN, Wang A, Decker M, Minshall RD, Liu MC, Clarke R. Caveolin-1 tyrosine phosphorylation enhances paclitaxel-mediated cytotoxicity. J Biol Chem. Feb 23 2007; 282(8): 5934-5943.
Jasmin JF, Frank PG, Lisanti MP. Caveolins and Caveolae. Advances in Experimental Medicine & Biology. 2005.
Fagerholm S, Ortegren U, Karlsson M, Ruishalme I, Stralfors P. Rapid insulin-dependent endocytosis of the insulin receptor by caveolae in primary adipocytes. PLoS One. Jun 19 2009; 4(6): e5985.
Yang Y, Tong Y, Gong M et al. Activation of PPARbeta/delta protects pancreatic beta cells from palmitate-induced apoptosis by upregulating the expression of GLP-1 receptor. Cell Signal. Feb 2014; 26(2): 268-278.